Constant Therapeutics LLC is a private biopharmaceutical company developing peptide and small molecule drugs that are agonists of the alternative renin angiotensin system, the protective arm of the renin angiotensin system (RAS). This protective pathway involves the enzyme ACE2, its principal product, the peptide angiotensin-(1-7), and the peptide’s targets, the Mas and MrgD receptors. Constant’s lead drug candidate is TXA127.